Physician profile
Chad Thomas Edmonds
NPI 1598265696
$2,794.76
in general payments reported to CMS, 2019-2025
16 companies · $1,127 in 2025
The $1,127 reported for 2025 was more than what 92% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $273 · 2020: $73.61 · 2021: $83.79 · 2022: $367 · 2023: $342 · 2024: $528 · 2025: $1,127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,798 · Travel and Lodging: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,798.05 |
| Travel and Lodging | $199.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $666.05 | 2021-2025 | Misight Contact Lens, Myday Contact Lens, Paragon Crt |
| Bausch & Lomb Americas INC. | $551.95 | 2022-2025 | Infuse, Biotrue One Day, Biotrue |
| Alcon Vision LLC | $473.63 | 2019-2025 | Clareon Panoptix Pro, Precision7, Total30 |
| Visioneering Technologies, INC. | $271.97 | 2019-2025 | |
| Johnson & Johnson Vision Care, INC. | $254.38 | 2019-2024 | |
| Oyster Point Pharma, INC. | $157.15 | 2022-2024 | Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $106.03 | 2019-2021 | |
| Lkc Technologies, INC. | $98.98 | 2024 | |
| Allergan, INC. | $56.52 | 2022 | |
| Shire North American Group INC | $46.95 | 2019 | |
| Astellas Pharma US INC | $27.85 | 2025 | Izervay |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Abb Con-Cise Optical Group LLC | $16.43 | 2023 | Spectacle Lenses, Contact Lens |
| Biotissue Holdings INC. | $15.82 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $14.41 | 2024 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Edmonds listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.